IRIS
CORTI, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.546
EU - Europa 4.991
NA - Nord America 2.871
SA - Sud America 1.545
AF - Africa 129
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 15.088
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.019
US - Stati Uniti d'America 2.752
SG - Singapore 2.115
CN - Cina 1.789
BR - Brasile 1.281
HK - Hong Kong 730
SE - Svezia 687
VN - Vietnam 505
FR - Francia 269
RO - Romania 269
IT - Italia 218
DE - Germania 181
AR - Argentina 106
IN - India 91
GB - Regno Unito 89
FI - Finlandia 77
BD - Bangladesh 55
EC - Ecuador 52
CA - Canada 44
ID - Indonesia 44
IE - Irlanda 44
MX - Messico 43
ZA - Sudafrica 43
AT - Austria 38
IQ - Iraq 31
CO - Colombia 29
PY - Paraguay 28
JP - Giappone 27
NL - Olanda 24
PL - Polonia 24
TR - Turchia 20
MA - Marocco 18
EG - Egitto 15
ES - Italia 15
PK - Pakistan 15
UZ - Uzbekistan 15
PE - Perù 13
SA - Arabia Saudita 13
VE - Venezuela 13
CL - Cile 11
AE - Emirati Arabi Uniti 10
KE - Kenya 10
UY - Uruguay 10
TN - Tunisia 9
UA - Ucraina 9
AZ - Azerbaigian 8
IR - Iran 8
LT - Lituania 8
NP - Nepal 8
PH - Filippine 8
DO - Repubblica Dominicana 7
AL - Albania 6
MY - Malesia 6
NG - Nigeria 6
DZ - Algeria 5
GE - Georgia 5
JO - Giordania 5
KR - Corea 5
KZ - Kazakistan 5
SN - Senegal 5
ET - Etiopia 4
JM - Giamaica 4
PA - Panama 4
AU - Australia 3
BB - Barbados 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
GA - Gabon 3
HR - Croazia 3
KW - Kuwait 3
LB - Libano 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BE - Belgio 2
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CY - Cipro 2
DM - Dominica 2
GT - Guatemala 2
IL - Israele 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
SV - El Salvador 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CD - Congo 1
CG - Congo 1
CH - Svizzera 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LY - Libia 1
Totale 15.079
Salva come PNG Salva come JPEG
Città #
Singapore 844
Hong Kong 724
Moscow 670
Dallas 513
San Jose 397
Ashburn 366
Shanghai 302
Hefei 287
Lawrence 266
Princeton 266
Lauterbourg 236
Ho Chi Minh City 180
São Paulo 119
Beijing 118
Hanoi 98
New York 91
Milan 79
Los Angeles 68
Helsinki 59
Rio de Janeiro 45
Dublin 41
Nuremberg 41
Santa Clara 38
Pune 34
Da Nang 30
Guangzhou 27
Boardman 24
Frankfurt am Main 24
Orem 24
The Dalles 24
Tokyo 24
Haiphong 22
Curitiba 21
Quito 21
London 20
Montreal 20
Warsaw 20
Johannesburg 19
Munich 19
Brasília 18
Campinas 18
Chennai 18
Denver 18
Columbus 17
Guarulhos 16
Hangzhou 16
Hải Dương 16
Stockholm 16
Vienna 16
Belo Horizonte 15
Dhaka 15
Mexico City 14
Rome 14
Salvador 14
Chicago 13
Goiânia 13
Manchester 13
Phoenix 13
Poplar 13
Shenzhen 13
Turku 13
Asunción 12
Baghdad 12
Brooklyn 12
Jakarta 12
Manaus 12
Porto Alegre 12
Santo André 12
Seattle 12
Tashkent 12
Thái Bình 12
Atlanta 11
Fortaleza 11
San Francisco 11
Xi'an 11
Biên Hòa 10
Cape Town 10
Guayaquil 10
Washington 10
Boston 9
Lima 9
Montevideo 9
Recife 9
Ribeirão Preto 9
Sorocaba 9
Thái Nguyên 9
Wuxi 9
Can Tho 8
Cesano Boscone 8
Houston 8
Riyadh 8
Santiago 8
Amsterdam 7
Baku 7
Cleveland 7
Duque de Caxias 7
Ha Long 7
Ipatinga 7
Joinville 7
Juiz de Fora 7
Totale 6.925
Salva come PNG Salva come JPEG
Nome #
A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer 383
Hematopoietic stem-and progenitor-cell gene therapy for hurler syndrome 133
Gold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer 125
Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome 123
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth 123
An innovative platform approach for the development of ex-vivo gene therapies for the treatment of lysosomal storage diseases with skeletal involvement 117
A pilot phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma 113
A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins 110
Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods 108
Altered Chromogranin A Circulating Levels in Meniere’s Disease 104
Chromogranin A plasma levels predict mortality in COVID-19 103
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 101
Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging 101
CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study 99
Aminopeptidase N (CD13)-positive bone marrow-derived cells induce angiogenesis and tumor growth: A potential non-malignant immune cell target against cancer 97
A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on α5β1-targeted gold nanorods 95
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 94
[Activation and role of the tumor necrosis factor-alpha in congestive heart failure]. FT Attivazione e ruolo del fattore di necrosi tumorale alfa nello scompenso cardiaco congestizio. 93
A receptor-antibody sandwich assay for teicoplanin. 90
Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis 85
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 85
A stapled chromogranin A-derived peptide is a potent dual ligand for integrins αvβ6 and αvβ8 84
A new method for rapid and simple pregnancy detection using gold-labelled antibodies 83
Production and characterisation of human recombinant single chain urokinase-type plasminogen activator from mouse cells 83
A rapid method for monitoring DNA labelling reactions with haptens. 83
A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator. 83
Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma 83
Chromogranin-A production and fragmentation in patients with Takayasu arteritis. 82
A new chromogranin A-dependent angiogenic switch activated by thrombin 81
Affinity enhancement of complementary peptide recognition 80
A novel aminopeptidase N/CD13 inhibitor selectively targets an endothelial form of CD13 after coupling to proteins 79
Agents regulating vascular permeability 72
Contrast enhanced photoacoustic detection of fibrillar collagen in the near infrared region-I 70
Quantification of Chromogranin A and Its Fragments in Biological Fluids 69
Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models 69
TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens 68
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α 67
A Pilot Study on Continuous Infusion of 4% Albumin in Critically Ill Patients: Impact on Nosocomial Infection via a Reduction Mechanism for Oxidized Substrates 66
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy 64
Won't you come on in? How to favor lymphocyte infiltration in tumors 63
Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces and iron-deficient phenotype 63
Tumor necrosis factor-α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the successful treatment of patients with infliximab 63
Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity 63
Tumor targeting with biotinylated tumor necrosis factor alpha: Structure-activity relationships and mechanism of action on avidin pretargeted tumor cells 62
Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study 62
Spatiotemporal regulation of tumor angiogenesis by circulating chromogranin a cleavage and neuropilin-1 engagement 62
Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action 61
Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif 61
Autocrine saturation of pro-urokinase receptors on human A431cells 61
Breaching the blood–brain tumor barrier for tumor therapy 61
The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells 60
Chromogranin A is preferentially cleaved into pro-angiogenic peptides in the bone marrow of multiple myeloma patients 60
Ways to improve tumor uptake and penetration of drugs into solid tumors 60
Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretion 60
Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides 59
Anti-idiotype monoclonal antibody directed against anti-TNF antibodies 59
T cells redirected to a minor histocompatibility antigen instruct intratumoral TNFα expression and empower adoptive cell therapy for solid tumors 59
Identification of an epitope of tumor-necrosis-factor (TNF) receptor-type-1 (p55) recognized by a TNF-alpha-antagonist monoclonal-antibody 59
Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy 58
Mode of interaction between tumor-necrosis-factor-alpha and a monoclonal-antibody expressing a recurrent idiotype 58
Tumour necrosis factor: Strategies for improving the therapeutic index 58
Liposome-Mediated Therapy of Neuroblastoma 58
Cytokine conjugates (IL-12 –peptide conjugates) 58
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer 57
Oxidative stress biomarkers and chromogranin A in uremic patients: Effects of dialytic treatment 57
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) 57
Cromogranina A per uso come reagente in un metodo diagnostico o prognostico 57
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism 57
The elusive role of proton pump inhibitors in COVID-19: Can plasma Chromogranin A levels hold the key? 56
Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha 56
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours 56
Anti-urokinase monoclonal antibody, matrix bearing it, test method, biochemical test kits which use it. 56
Receptor-antibody sandwich assay. 56
Chromogranin A and the Tumor Microenvironment 56
Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms 56
Oxidation-induced structural changes of ceruloplasmin foster NGR-motifs deamidation that promote integrin binding and signaling 56
Chromogranin A and Its Fragments in the Critically Ill: An Expanding Domain of Interest for Better Care 55
Structure-activity relationships of chromogranin A in cell adhesion - Identification of an adhesion site for fibroblasts and smooth muscle cells 55
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells 55
PCR amplification of antibody variable regions using primers that anneal to constant regions 55
Chromogranin A Regulates Tumor Self-Seeding and Dissemination 55
Tumor-necrosis-factor (TNF)-alpha quantification by ELISA and bioassay - effects of TNF-alpha-soluble TNF-receptor (p55) complex dissociation during assay incubations 55
Monoclonal antibodies against the TNF type-I receptor, process for their production and use thereofAnticorpi monoclonali anti-recettore di tipo 1 del TNF alfa, procedimento per la loro produzione e loro uso 55
NF-kappa B-mediated regulation of urokinase gene expression by PMA and TNF-alpha in human A549 cells 55
Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability 54
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas 54
Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): assessment of severity in patients with sepsis. 54
Tumor necrosis factor in heart failure 54
Mechanism of suramin-induced deoligomerization of tumor-necrosis-factor-alpha 54
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 54
CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis 54
Immobilized oligopeptides 54
Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αvβ3 without Promoting Integrin Allosteric Activation 54
Nanogold Functionalized With Lipoamide-isoDGR: A Simple, Robust and Versatile Nanosystem for αvβ3-Integrin Targeting 54
Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors 53
Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium? 53
NGR-Tagged Nano-Gold: a new CD13-selective carrier for cytokine delivery to tumors 53
Oligomeric Tumor-necrosis factor alpha slowly converts into inactive forms at bioactive levels 53
Physiological levels of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity 53
Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications, and alternative roads 52
Totale 7.326
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.913
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.913
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022111 0 0 0 70 0 7 7 5 2 2 1 17
2022/20231.296 604 245 115 3 2 138 42 67 64 5 5 6
2023/2024417 5 8 62 36 26 88 24 33 0 18 37 80
2024/20253.632 461 37 54 101 80 265 744 277 649 504 226 234
2025/20269.687 698 934 771 1.635 678 199 945 746 2.734 347 0 0
Totale 15.229